AXSM (Axsome Therapeutics) Total Assets: $713.6 Mil (As of Mar. 2026)


AXSM Axsome Therapeutics Inc AXSM
52 GF Score
Price $241.67
GF Value $220.41
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics Total Assets?

Axsome Therapeutics AXSM +1.83% 52 Total Assets is $713.6 Mil as of Mar. 2026. GuruFocus rates AXSM with a GF Score™ of 52/100 and a GF Value™ of $220.41 (Fairly Valued). The stock has 4 warning signs investors should review.

Axsome Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $713.6 Mil.

During the past 12 months, Axsome Therapeutics's average Total Assets Growth Rate was 38.10% per year. During the past 3 years, the average Total Assets Growth Rate was 41.10% per year. During the past 5 years, the average Total Assets Growth Rate was 229.00% per year. During the past 10 years, the average Total Assets Growth Rate was 96.10% per year.

During the past 13 years, Axsome Therapeutics's highest 3-Year average Total Assets Growth Rate was 507.00%. The lowest was -28.50%. And the median was 75.10%.

Total Assets is connected with ROA %. Axsome Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -36.79%. Total Assets is also linked to Revenue through Asset Turnover. Axsome Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.27.

Axsome Therapeutics  (NAS:AXSM) Total Assets Explanation

Total Assets is connected with ROA %.

Axsome Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-258.168/( (689.805+713.607)/ 2 )
=-258.168/701.706
=-36.79 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Axsome Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=191.203/( (689.805+713.607)/ 2 )
=191.203/701.706
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Axsome Therapeutics Total Assets Related Terms

Axsome Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Axsome Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics Total Assets Chart

Axsome Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 87.79 331.48 588.24 568.50 689.81

Axsome Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 596.67 639.79 669.25 689.81 713.61
AXSM
52GF Score
Axsome Therapeutics Inc AXSM
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axsome Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Axsome Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=88.295+601.51
=689.8

Axsome Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=54.587+659.02
=713.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $713.6 Mil mean?
Axsome Therapeutics (AXSM) has a Total Assets of $713.6 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Axsome Therapeutics and its competitors.
Is Axsome Therapeutics' Total Assets too high?
Axsome Therapeutics' current Total Assets is $713.6 Mil. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Total Assets compare to IONS and EXEL?
Axsome Therapeutics' Total Assets of $713.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current Total Assets is $713.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Fairly Valued. The stock's GF Value™ is $220.41, compared to a current price of $241.67 — trading 9.6% above its estimated fair value. The current Total Assets is $713.6 Mil. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current Total Assets is $713.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (AXSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of $241.67 is trading 9.6% above its estimated GF Value™ of $220.41. GuruFocus considers Axsome Therapeutics to be Fairly Valued.

Key valuation signals for AXSM:

  • Total Assets: $713.6 Mil
  • GF Value™: $220.41 vs. price of $241.67 (9.6% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score

Get the complete analysis for AXSM

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$241.67
Price
$220.41
GF Value